After a debate that has divided officials within the US Food and Drug Administration (FDA), an advisory committee to the federal agency yesterday voted to keep the diabetes drug Avandia (rosiglitazone) made by GlaxoSmithKline on the market. This was just after the same panel had overwhelmingly decided that the drug raised the risk of heart attack and other heart problems. [click link for full article]
More...